1832 Asset Management L.P. Sells 2,695 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• 1832 Asset Management L.P. reduced its holdings in Regeneron Pharmaceuticals by 56.3% during the first quarter, now owning 2,092 shares valued at approximately $1.3 million.
• Multiple analysts have revised their ratings on Regeneron, with Truist Financial lowering its price target from $940.00 to $812.00, while Canaccord Genuity maintains a buy rating with a target of $850.00.
• Regeneron recently declared a quarterly dividend of $0.88 per share, with an annual yield of 0.6%, scheduled for payment on September 3rd.

1832 Asset Management L.P. lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 56.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,092 shares of the biopharmaceutical company's stock after selling 2,695 shares during the period. 1832 Asset Management L.P.'s holdings in Regeneron Pharmaceuticals were worth $1,327,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of REGN. Marietta Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after purchasing an additional 2,501 shares during the last quarter. GAMMA Investing LLC raised its holdings in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after acquiring an additional 955 shares during the period. KBC Group NV raised its holdings in Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after acquiring an additional 12,793 shares during the period. Finally, Lmcg Investments LLC raised its holdings in Regeneron Pharmaceuticals by 231.3% in the 1st quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock valued at $9,184,000 after acquiring an additional 10,110 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $7.35 during trading hours on Thursday, hitting $579.61. 616,549 shares of the stock were exchanged, compared to its average volume of 1,082,231. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,210.97. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a market cap of $61.43 billion, a PE ratio of 14.61, a price-to-earnings-growth ratio of 1.96 and a beta of 0.33. The company's fifty day simple moving average is $555.84 and its two-hundred day simple moving average is $588.67.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the business posted $11.56 earnings per share. The company's quarterly revenue was up 3.6% on a year-over-year basis. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on REGN. Citigroup reissued a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Canaccord Genuity Group restated a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.